Barely Significant
← all excerpts

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).

Lancet Reg Health Eur · 2023 · PMC10350848 · PMID 37465323

Europe PMCDOI
1
hedged sentence
0.2500
closest p · 5.0× alpha
0.2500
boldest claim

The sentences

did not reach statistical significancep = 0.25not close (p > 0.1)
Three patients in the roflumilast group had PASI90 or PASI100 responses, but the difference did not reach statistical significance versus placebo (n = 0 patients; p = 0.25 and p = 0.49, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.